Can a lighter treatment beat aggressive breast cancer?
NCT ID NCT07271992
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing whether a combination of two drugs—sacituzumab govitecan (a targeted chemotherapy) and tislelizumab (an immunotherapy)—can effectively treat early-stage triple-negative breast cancer with a less intense approach. The study will enroll 30 people and use specific biomarkers (Trop-2 and PD-L1) to identify who might benefit most. The main goal is to see how many patients have no cancer left after treatment, while also monitoring safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sacituzumab govitecan plus tislelizumab (a chemotherapy-antibody combo and an immunotherapy drug)
What this could lead to
If successful, this could show that some people with early triple-negative breast cancer can be treated effectively with a less intense combination, reducing side effects while still achieving a complete response.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The treatment still carries risks like immune-related side effects and chemotherapy toxicity, and it is not yet known if it works better than standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.